Frontlight ResearchEarly access
CompletedNo phase
The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest
Key facts
- Who runs it
- Western University, Canada
- Where
- Boston, Falls Church, Honolulu, Los Angeles, Nashville, Portland, Saint Paul, Salt Lake City, San Diego, San Francisco, and Stanford, United StatesSee the 11 sitesAlso in 2 other countries, 10 sites
- Trial code
- Status
- Completed
- People taking part
- 100 people enrolled
- Started
- 1 May 2017
- Ended
- 1 Jun 2025
- Type of study
- Observational
- Treatments tested
- Invasive Electrophysiology Study
- Record updated
- 15 June 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Unexplained cardiac arrest requiring cardioversion or defibrillation
- Willing and able to sign informed consent
Who cannot take part
- Type I Brugada ECG with >/= 2 mm ST elevation in V1 and/or V2 (Spontaneous or Drug-Induced)
- Coronary artery disease (stenosis > 50%) and clinical findings consistent with an ischemic arrest
- Arrhythmic mitral valve prolapse syndrome
- Reduced left ventricular function (left ventricular ejection fraction < 50%) on echocardiogram or cardiac MRI
- Persistent resting QTc > 460 msec for males and 480 msec for females
- Resting QTc < 350 msec
- Reversible cause of cardiac arrest such as marked hypokalemia (<2.8 mmol/l) or drug overdose sufficient in severity without other cause to explain the cardiac arrest
- Polymorphic or bidirectional ventricular tachycardia observed with exertion on exercise treadmill testing
- Clinical, electrocardiographic, and/or imaging findings consistent with a diagnosis of arrhythmogenic right ventricular cardiomyopathy
- Myocarditis
- Documented ventricular fibrillation initiated by a short-coupled premature ventricular contraction
Where in United States
Also in 2 other countries, 10 sites
- Massachusetts General HospitalBoston, United States
- Inova Heart and Vascular InstituteFalls Church, United States
- Queen's Medical CenterHonolulu, United States
- UCLA Medical CenterLos Angeles, United States
- Vanderbilt University Medical CenterNashville, United States
- Oregon Health Science UniversityPortland, United States
- Regions HospitalSaint Paul, United States
- University of UtahSalt Lake City, United States
- UC San Diego Health SystemSan Diego, United States
- UCSF Medical CenterSan Francisco, United States
- Stanford UniversityStanford, United States
About the trial
What the trial wants to find out
Sudden cardiac death (SCD) remains a major cause of mortality within developed nations despite aggressive efforts to reduce its societal burden. Despite extensive clinical and genetic investigations, a subgroup of cardiac arrests remain unexplained, highlighting the potential contribution of additional cardiac conditions that may not be identified with contemporary diagnostic algorithms. The EPS ARREST study aims to evaluate the role of invasive electrophysiology study within this patient population.
The group in the trial
- Unexplained Aborted Cardiac Arrest
Survivors of sudden cardiac death with no identifiable etiology following initial diagnostic workup.
Treatment: Invasive Electrophysiology Study
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 15 June 2025